ArticleJournal of proteome research2009
Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma.
Article in Journal of proteome research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test.Cancers · 2021Article
- Tandem Mass Tag-Based Proteomic Analysis of Potential Biomarkers for Hepatocellular Carcinoma Differentiation.OncoTargets and therapy · 2021Article
- iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis.Journal of Cancer · 2019Article
- Proteomic profiling in liver cancer: another new page.Translational gastroenterology and hepatology · 2019Article
- Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis.Scientific reports · 2018Article
- Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma.World journal of gastroenterology · 2018Article
- Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma.Proteomes · 2017Article
- Quantitative proteomic analysis for high-throughput screening of differential glycoproteins in hepatocellular carcinoma serum.Cancer biology & medicine · 2015Article
- Comparative study of Hsp27, GSK3β, Wnt1 and PRDX3 in Hirschsprung's disease.International journal of experimental pathology · 2014Article
- Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection.Brain and behavior · 2014Article
- Over-expressed Testis-specific Protein Y-encoded 1 as a novel biomarker for male hepatocellular carcinoma.PloS one · 2014Article
- The Role of Mass Spectrometry in the "Omics" Era.Current organic chemistry · 2013Article
- Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.Journal of translational medicine · 2013Article
- Alpha-fetoprotein: a renaissance.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.PloS one · 2013Article
- Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.Journal of virology · 2012Article
- Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2012Article
- Dickkopf 4 (DKK4) acts on Wnt/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma.Oncogene · 2012Article
- Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 4 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is an aggressive liver cancer but clinically validated biomarkers that can predict natural history of malignant progression are lacking. The present study explored the proteome-wide patterns of HCC to identify biomarker signature that could distinguish cancerous and nonmalignant liver tissues. A retrospective cohort of 80 HBV-associated HCC was included and both the tumor and adjacent nontumor tissues were subjected to proteome-wide expression profiling by 2-DE method. The subjects were randomly divided into the training (n = 55) and validation (n = 25) subsets, and the data analyzed by classification-and-regression tree algorithm. Protein markers were characterized by MALDI-ToF/MS and confirmed by immunohistochemistry, Western blotting and qPCR assays. Proteomic expression signature composed of six biomarkers (haptoglobin, cytochrome b5, progesterone receptor membrane component 1, heat shock 27 kDa protein 1, lysosomal proteinase cathepsin B, keratin I) was developed as a classifier model for predicting HCC. We further evaluated the model using both leave-one-out procedure and independent validation, and the overall sensitivity and specificity for HCC both are 92.5%, respectively. Clinical correlation analysis revealed that these biomarkers were significantly associated with serum AFP, total protein levels and the Ishak's score. The described model using biomarker signatures could accurately distinguish HCC from nonmalignant tissues, which may also provide hints on how normal hepatocytes are transformed to malignant state during tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.